You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Topotecan for the treatment of relapsed small-cell lung cancer

  • Technology appraisal guidance
  • Reference number: TA184
  • Published:  25 November 2009
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Lung cancer (small-cell, second line treatment) - topotecan: evaluation report

  • Lung cancer (small-cell, second line treatment) - topotecan: overview

  • Lung cancer (small-cell, second line treatment) - topotecan: assessment report

  • Lung cancer (small-cell, second line treatment) - topotecan: Consultee and commentator comments on the assessment report

  • Lung cancer (small-cell, second line treatment) - topotecan: Assessment Group response to manufacturer comments on the Assessment Report

  • Lung cancer (small-cell, second line treatment) - topotecan: Non-manufacturer submissions

  • Lung cancer (small-cell, second line treatment) - topotecan: Manufacturer submission

  • Lung cancer (small-cell, second line treatment) - topotecan: Expert written personal statements


This page was last updated: 30 March 2010

Back to top